11 results on '"Cheung, Ramsey"'
Search Results
2. Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study.
- Author
-
Kam, Leslie Y., Yeo, Yee Hui, Ji, Fanpu, Henry, Linda, Cheung, Ramsey, and Nguyen, Mindie H.
- Subjects
HEPATITIS C ,HEPATOCELLULAR carcinoma ,HEPATITIS C virus ,HEPATITIS ,RACE ,ANTIVIRAL agents - Abstract
Summary: Background: Since the inception of the interferon‐free direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection, guidelines as to who should receive this potentially curative treatment have evolved. Treatment with DAAs is now considered for all patients except for those considered moribund. Aim: To determine the DAA treatment rate for patients with HCV‐related hepatocellular carcinoma (HCC). Methods: This was a retrospective study from January 2015 to March 2021 of a national sample of privately insured patients with HCV‐related HCC using Optum's Clinformatics® Data Mart (CDM) Database – a large, de‐identified, adjudicated claims database. Results: We identified 3922 patients with HCV‐related HCC: 922 (23.5%) received DAA. Compared to untreated patients, DAA‐treated patients were younger (65.2 ± 7.5 vs. 66.4 ± 7.5 years, p < 0.001), more frequently saw a gastroenterology/infectious disease (GI/ID) physician (41.2% vs. 34.2%), and had decompensated cirrhosis (56% vs. 53%, p = 0.001). In multivariable analysis, younger age (HR: 0.98, 95% CI: 0.97–0.99, p < 0.001), GI/ID care (HR: 3.06, 95% CI: 2.13–4.51, p < 0.001), and having cirrhosis (compensated: HR: 1.60, 95% CI: 1.18–2.21, p = 0.003; decompensated: HR: 1.45, 95% CI: 1.07–1.98, p = 0.02) were associated with receiving DAA treatment, but not sex, race, or ethnicity. DAA‐treated patients had significantly higher 5‐year survival than untreated patients (47.2% vs. 35.2%, p < 0.001). Following adjustment for age, sex, race/ethnicity, Charlson Comorbidity Index, and HCC treatment, receiving DAA treatment was associated with lower mortality (aHR: 0.61, 95% CI: 0.53–0.69, p < 0.001). Conclusion: DAA treatment remains underutilised in insured patients with HCV‐related HCC; fewer than one in four patients received treatment. Seeing a specialist and having decompensated cirrhosis were predictors for DAA treatment; additional efforts are needed to increase awareness of HCV treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review
- Author
-
Dyal, Harleen K., Aguilar, Maria, Bartos, Gabriella, Holt, Edward W., Bhuket, Taft, Liu, Benny, Cheung, Ramsey, and Wong, Robert J.
- Published
- 2016
- Full Text
- View/download PDF
4. Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
- Author
-
Veracruz, Nicolette, Gish, Robert G., Cheung, Ramsey, Chitnis, Amit S., and Wong, Robert J.
- Subjects
COVID-19 ,HEPATITIS B ,HEPATOCELLULAR carcinoma ,VIRAL hepatitis ,HEPATITIS C virus ,HEPATITIS B virus ,CIRRHOSIS of the liver ,DISEASE incidence - Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) contribute to significant healthcare burden globally. We aim to provide an updated and comprehensive analysis of global trends in the incidence and mortality of HBV and HCV related acute infections, cirrhosis and hepatocellular carcinoma (HCC). Estimates of annual cause‐specific disease incidence and mortality for HBV and HCV were analysed using the 2010–2019 Global Burden of Diseases, Injuries and Risk Factors Study database. Three distinct disease states were evaluated: acute infections, cirrhosis and HCC. Age‐standardized disease incidence and mortality were presented per 100,000 population and stratified by age, sex, year and 21 world regions. From 2010 to 2019, overall incidence of acute HBV declined by 19.3% (95% CI 4.1–32.0, p <.05) and HBV cirrhosis declined by 15.0% (95% CI 9.8–20.7, p <.05). Incidence of HCV cirrhosis increased by 5.6% (95% CI 0.3–10.2, p <.05) and HCV HCC remained stable. Incidence of acute HCV declined until 2015, after which it began increasing. From 2010 to 2019, overall mortality for HBV cirrhosis and HCV cirrhosis declined, whereas mortality for acute infections and HCC remained stable. Major differences in HBV and HCV incidence and mortality trends were observed when stratified by world regions. In conclusion, while our analyses of global trends in HBV and HCV incidence and mortality demonstrate encouraging trends, disparities in disease epidemiology were observed across world regions. These observations will identify regions and populations where greater focus and resources are needed to continue progressing towards viral hepatitis elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Utilization of Antiviral Therapy for Patients With Hepatitis B–Related Hepatocellular Carcinoma: A Nationwide Real-World US Study.
- Author
-
Kudaravalli, Sahith, Kam, Leslie Y., Huang, Daniel Q., Cheung, Ramsey, and Nguyen, Mindie H.
- Abstract
Although oral antiviral therapy (OAV) is reported to improve outcomes in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), it is underutilized. We determined the rate and factors associated with OAV utilization among patients with HBV-related HCC in a US population with health insurance. Patients with HBV-related HCC were identified from the de-identified administrative health claims database for patients with private insurance, Optum Clinformatics (2003–2021). We identified 2129 patients with HBV-related HCC: 71% male, mean age 62.7 ± 12.5 years, 40% Asian individuals, 72% with cirrhosis, and 37% received OAV. The treatment rate improved over time (40.5% after 2010 vs 26.3% earlier; P <.001). Significantly lower treatment rates were noted for females, non-Asian patients, noncirrhotic patients, and patients without gastroenterologist/hepatologist or infectious disease (GI/ID) specialist care (P <.0001). OAV treatment predictors included Asian race and ethnicity (adjusted odds ratio [aOR], 3.6; 95% CI, 2.8–4.5; P <.001), male sex (aOR, 1.6; 95% CI, 1.3–2.0; P <.001), seeing a GI/ID specialist (aOR, 1.5; 95% CI, 1.10–1.99; P =.0091), having compensated cirrhosis (aOR, 2.2; 95% CI, 1.7–2.8; P <.001), and being treated from 2011 to 2021 (aOR, 2.3; 95% CI, 1.8–3.0; P <.001); being younger (aOR, 0.98; 95% CI, 0.98–0.99; P <.001) was less likely for treatment. OAV initiated at or before HCC diagnosis was associated independently with improved survival (adjusted hazard ratio, 0.84; 95% CI, 0.72–0.99; P =.037). Among patients with HBV-related HCC, only 1 in 3 received OAV despite having insurance coverage. Efforts must continue to develop ways to improve HBV OAV treatment, especially among females, non-Asian patients, and patients without cirrhosis or not seen by specialists. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score.
- Author
-
Wong, Robert J., Devaki, Pardha, Long Nguyen, Cheung, Ramsey, Cho-Phan, Cheryl, and Nguyen, Mindie H.
- Abstract
Background & Aims Assignment of Model for End-stage Liver Disease (MELD) exception points to patients with hepatocellular carcinoma (HCC) who fall within Milan criteria, which began in 2003, increases their priority on liver transplantation waitlists. However, little is known about how this change affected survival of all patients with HCC (transplant eligible and ineligible). We compared long-term survival of HCC patients before and after this change. Methods We performed a large population-based cohort study by using the Surveillance, Epidemiology, and End Results cancer registry to investigate survival times of patients with HCC before those who met the Milan criteria were given MELD exception points (1998-2003) and afterward (2004-2010) by using Kaplan-Meier methods. Multivariate Cox proportional hazards models evaluated independent predictors of survival. Results During 2004-2010, a significantly higher percentage of patients with HCC survived for 5 years compared with 1998-2003 (21.9% vs 13.0%, P < .001). This difference remained significant among all treatment groups (no therapy: 15.2% vs 10.2%, P < .001; local tumor destruction: 37.6% vs 22.1%, P < .001; resection: 55.5% vs 39.2%, P < .001; transplantation: 77.2% vs 73.1%, P = .12). Multivariate Cox proportional hazards models, inclusive of sex, age, ethnicity, Milan criteria, number and stage of tumor, and time period, showed increased survival of patients during 2004-2010 (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.83-0.91; P < .001). Compared with non-Hispanic whites, Asians (HR, 0.81; 95% CI, 0.77-0.86; P < .001) and Hispanics (HR, 0.89; 95% CI, 0.84-0.95; P < .001) had longer survival times, whereas blacks had a trend toward shorter survival times (HR, 1.05; 95% CI, 0.98-1.13; P = .16). Conclusions Patients with HCC who met Milan criteria had significantly longer survival times after implementation of the MELD exception points, regardless of sex or ethnicity. Blacks continued to have the lowest rates of 5-year survival. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. HEPATITIS G VIRUS: CLINICAL RELEVANCE AND RESPONSIVENESS TO INTERFERON.
- Author
-
Cheung, Ramsey C. and Keeffe, Emmet B.
- Subjects
HEPATITIS viruses ,HEPATITIS ,HEPATITIS C ,LIVER cancer ,RNA - Abstract
Explores the effect of interferon on serum hepatitis G virus (HGV) RNA. Diagnosis of HGV infection; Prevalence of HGV in the general population; Evidence that HGV causes liver cancer; Impact of HGV coinfection on the clinical course of hepatitis C.
- Published
- 1997
8. Hepatitis B: Treating chronic cases.
- Author
-
Bobbala, Manjula and Cheung, Ramsey
- Subjects
- *
HEPATITIS B treatment , *LIVER diseases , *CIRRHOSIS of the liver , *LIVER cancer , *HEPATITIS viruses , *ANTIGENS - Abstract
The article focuses on the treatment in the chronic cases of Hepatitis B. Chronic hepatitis B put the patient at risk for cirrhosis and hepatocellular carcinoma. The number of patients that die from hepatitis B virus infection in the U.S. is estimated to be 5,000. Hepatitis B surface antigen (HBsAg) becomes undetectable in self-limiting acute disease. It is accompanied by the development of antibody to HBsAg. The infection is considered chronic if the patient continues to test positive for HBsAg six months after an acute infection.
- Published
- 2006
9. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.
- Author
-
Tran, Sally, Donghak Jeong, Henry, Linda, Cheung, Ramsey C., and Nguyen, Mindie H.
- Subjects
- *
PATIENT monitoring , *LIVER cancer , *CHRONIC hepatitis B , *PATIENT compliance , *COHORT analysis , *PUBLIC health - Abstract
INTRODUCTION: Previous studies, mostly small and single center, have shown gaps in the evaluation and monitoring of patients with chronic hepatitis B (CHB) virus infection. We aimed to examine the rates and predictors of adherence to guidelines for CHB care in a large nationwide cohort. METHODS: Weidentified adult patients withCHBinfection from the Truven MarketScan databases of commercially insured and Medicare patients with private insurance supplement (2007-2014) using International Classification of Diseases, Ninth Revision, Clinical Modification codes. The initial evaluation cohort had at least 6 months follow-up, whereas at least 12 months was required for the long-term monitoring cohort. RESULTS: We analyzed 55,317 eligible patients with CHB infection: mean age 46 6 12 years, 58% men, and 14.8% with cirrhosis. Over a mean follow-up of 3.262.3 years, 55.8% had specialist (gastroenterology or infectious diseases) visits. For initial evaluation, 59% of patients received both alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA tests, whereas only 33% had ALT, HBV DNA, and hepatitis B e antigen tests, with higher frequencies among patients with specialist visits. For longterm monitoring, only 25% had both ALT and HBV DNA tests performed annually. Among patients at higher risk of developing hepatocellular carcinoma (patients with cirrhosis, male patients without cirrhosis older than 40 years, and female patients without cirrhosis older than 50), less than 40% underwent annual hepatocellular carcinoma surveillance, with25%never receiving surveillance during the study period. Predictors of optimal initial evaluation and long-term monitoring were compensated cirrhosis (odds ratio: 1.60 and 1.47, respectively) and specialist visits (odds ratio: 1.86 and 1.31, respectively) (both P < 0.001). DISCUSSION: In this large cohort of patients with CHB infection with private insurance or Medicare with private insurance supplement, we observed poor adherence to the recommended initial evaluation and longterm monitoring. Among the predictors of adherence were specialist visits. Further efforts are needed to identify barriers and improve access to care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
- Author
-
Nguyen, Mindie H., Masanori Atsukawa, Toru Ishikawa, Satoshi Yasuda, Keisuke Yokohama, Trinh, Huy N., Taeang Arai, Shinya Fukunishi, Eiichi Ogawa, Yao-Chun Hsu, Mayumi Maeda, Hansen Dang, Cheng-Hao Tseng, Hirokazu Takahashi, Dae Won Jun, Tsunamasa Watanabe, Makoto Chuma, Akito Nozaki, Norifumi Kawada, and Cheung, Ramsey
- Subjects
- *
TENOFOVIR , *HEPATITIS B treatment , *HEPATOCELLULAR carcinoma , *LIVER cancer , *HYPERTENSION - Abstract
INTRODUCTION: Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch. METHODS: ETV-treated (≥12 months) chronic hepatitisBpatients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression (CVS) rate (HBV DNA <20 IU/mL). RESULTS: We analyzed 425 eligible patients (mean age 60.7613.2 years, 60% men, 90.8%Asian, 20.7% with diabetes, 27% with hypertension, 14.8% with cirrhosis, 8.3% with hepatocellular carcinoma, and mean ETV duration before switch 6.16 ± 3.17 years). The mean baseline estimated glomerular filtration rate (eGFR) was 89619 (chronic kidney disease [CKD] stages: 55.6% stage 1, 35.7% stage 2, and 8.8% stages 3-5). CVS rate increased from 91.90% at switch (from 90.46% 24 weeks before switch) to 95.57% and 97.21%at 48 and 96 weeks after (P = 0.03 and 0.02, respectively). Over the 96 weeks after switch, mean HBV DNA (P < 0.001) but not alanine aminotransferase or CKD stage decreased. Between switch and 96-week follow-up, 11% (26/235) of CKD stage 1 patients migrated to stage 2 and 8% (12/151) of stage 2 patients to stages 3-5, whereas 18% (27/151) from stage 2 to 1, and 19% (7/37) from stages 3-5 to 2. On multivariable generalized estimated equation analysis adjusted for age, sex, hypertension, diabetes, and cirrhosis, baseline eGFR, age (P < 0.001), and CKD stages 2 and 3-5 (vs 1) (both P < 0.001) were associated with lower follow-up eGFR. DISCUSSION: After an average of ± years on ETV, CVS increased from 91.9% at TAF switch to 97.2% at 96 weeks later. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival.
- Author
-
Yan, Melissa, Ha, John, Aguilar, Maria, Bhuket, Taft, Liu, Benny, Gish, Robert G., Cheung, Ramsey, and Wong, Robert J.
- Subjects
- *
LIVER cancer , *HEALTH equity , *HEALTH outcome assessment , *BABY boom generation - Abstract
Background & Aims Individuals born between 1945 and 1965 account for nearly 75% of hepatitis C virus (HCV) infections in the United States. As this cohort ages, progressive HCV-related liver disease leading to cirrhosis and hepatocellular carcinoma (HCC) will place a significant burden on the healthcare system. We aim to evaluate birth cohort-specific disparities in HCC stage at diagnosis, treatment rates, and overall survival with a focus on the 1945–1965 birth cohort. Methods A population-based retrospective cohort study of adult patients with HCC identified in the Surveillance, Epidemiology, and End Results 2003–2011 registry evaluated birth cohort-specific disparities in the prevalence and outcomes of HCC, including multivariate logistic regression models to evaluate disparities in HCC stage at diagnosis and HCC treatment received. Birth cohort-specific survival was evaluated with Kaplan–Meier methods and multivariate Cox proportional hazard models. Results The proportion of HCC represented by the 1945–1965 cohort increased by 64% from 2003–2011, and accounted for 57.4% of all HCC in 2011. Compared to patients born after 1965, the 1945–1965 cohort were more likely to have HCC within Milan criteria (OR, 3.66; 95% CI, 3.13–4.28; p < 0.001). However, among patients with HCC within Milan criteria, the 1945–1965 cohort had no difference in receipt of surgical treatment, but had higher overall long-term survival (HR, 0.82; 95% CI, 0.69–0.97; p < 0.03). Conclusions The 1945–1965 birth cohort accounts for the majority of HCC in the United States. Despite earlier HCC stage at diagnosis, no difference in receipt of surgical treatment was observed, but higher overall survival was achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.